Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1)

Pharmaceutical Research

Volumn 21, Issue 6, 2004, Pages 904-913

  Pauli Magnus, Christiane ^a   Kroetz, Deanna L ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ABCB1; drug resistance; MDR1; polymorphism

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCEIN; COLCHICINE; CYCLOSPORIN; CYCLOSPORIN A; DACTINOMYCIN; DIGOXIN; DOXORUBICIN; FEXOFENADINE; GENE PRODUCT; GLYCOPROTEIN P; LOPERAMIDE; MEMBRANE PROTEIN; NELFINAVIR; NORTRIPTYLINE; PACLITAXEL; RHODAMINE 123; TACROLIMUS; TALINOLOL; VALSPODAR; VERAPAMIL; VINBLASTINE;

ALLELE; AMINO ACID SUBSTITUTION; BILE; BLOOD BRAIN BARRIER; BRAIN PROTECTION; CELL TRANSPORT; DISEASE COURSE; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; ENZYME SPECIFICITY; EXCRETION; GENE; GENE FUNCTION; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; IN VITRO STUDY; INTESTINE ABSORPTION; MULTIDRUG RESISTANCE 1 GENE; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTECTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; STRUCTURE ANALYSIS; TESTIS; TISSUE; TOXICITY; URINE;

EID: 3042767682     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000029276.21063.0b     Document Type: Review

References (68)

1. C. J. Chen, D. Clark, K. Ueda, I. Pastan, M. M. Gottesman, and I. B. Roninson. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J. Biol. Chem. 265:506-514 (1990).
2. J. E. Chin, R. Soffir, K. E. Noonan, K. Choi, and I. B. Roninson. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol. Cell. Biol. 9:3808-3820 (1989).
3. A. Fojo, R. Lebo, N. Shimizu, J. E. Chin, I. B. Roninson, G. T. Merlino, M. M. Gottesman, and I. Pastan. Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat. Cell Mol. Genet. 12:415-420 (1986).
4. T. W. Loo and D. M. Clarke. The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface. J. Biol. Chem. 274:24759-24765 (1999).
5. B. Greiner, M. Eichelbaum, P. Fritz, H. P. Kreichgauer, O. von Richter, J. Zundler, and H. K. Kroemer. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104:147-153 (1999).
6. R. B. Kim, M. F. Fromm, C. Wandel, B. Leake, A. J. Wood, D. M. Roden, and G. R. Wilkinson. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289-294 (1998).
7. A. H. Schinkel, C. A. Mol, E. Wagenaar, L. van Deemter, J. J. Smit, and P. Borst. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur. J. Cancer 31A:1295-1298 (1995).
8. A. H. Schinkel, E. Wagenaar, C. A. Mol, and L. van Deemter. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:2517-2524 (1996).
9. C. J. Chen, J. E. Chin, K. Ueda, D. P. Clark, I. Pastan, M. M. Gottesman, and I. B. Roninson. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381-389 (1986).
10. M. M. Baekelandt, R. Holm, J. M. Nesland, C. G. Trope, and G. B. Kristensen. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res. 20:1061-1067 (2000).
11. I. O. Ng, C. L. Liu, S. T. Fan, and M. Ng. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am. J. Clin. Pathol. 113:355-363 (2000).
12. C. Wuchter, K. Leonid, V. Ruppert, M. Schrappe, T. Buchner, C. Schoch, T. Haferlach, J. Harbott, R. Ratei, B. Dorken, and W. D. Ludwig. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 85:711-721 (2000).
13. M. M. Gottesman, I. Pastan, and S. V. Ambudkar. P-glycoprotein and multidrug resistance. Curr. Opin. Genet. Dev. 6:610-617 (1996).
14. A. H. Schinkel, E. Wagenaar, L. van Deemter, C. A. Mol, and P. Borst. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:1698-1705 (1995).
15. A. Seelig, X. L. Blatter, and F. Wohnsland. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison. Int. J. Clin. Pharmacol. Ther. 38:111-121 (2000).
16. R. B. Kim, C. Wandel, B. Leake, M. Cvetkovic, M. F. Fromm, P. J. Dempsey, M. M. Roden, F. Belas, A. K. Chaudhary, D. M. Roden, A. J. Wood, and G. R. Wilkinson. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 16:408-414 (1999).
17. L. Becquemont, C. Verstuyft, R. Kerb, U. Brinkmann, M. Lebot, P. Jaillon, and C. Funck-Brentano. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin. Pharmacol. Ther. 70:311-316 (2001).
18. D. Durr, B. Stieger, G. A. Kullak-Ublick, K. M. Rentsch, H. C. Steinert, P. J. Meier, and K. Fattinger. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 68:598-604 (2000).
19. N. Kioka, J. Tsubota, Y. Kakehi, T. Komano, M. M. Gottesman, I. Pastan, and K. Ueda. P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochem. Biophys. Res. Commun. 162:224-231 (1989).
20. L. A. Mickley, J. S. Lee, Z. Weng, Z. Zhan, M. Alvarez, W. Wilson, S. E. Bates, and T. Fojo. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 91:1749-1756 (1998).
21. R. B. Kim, B. F. Leake, E. F. Choo, G. K. Dresser, S. V. Kubba, U. I. Schwarz, A. Taylor, H. G. Xie, J. McKinsey, S. Zhou, L. B. Lan, J. D. Schuetz, E. G. Schuetz, and G. R. Wilkinson. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70:189-199 (2001).
22. D. L. Kroetz, C. Pauli-Magnus, L. M. Hodges, C. C. Huang, M. Kawamoto, S. J. Johns, D. Stryke, T. E. Ferrin, J. DeYoung, T. Taylor, E. J. Carlson, I. Herskowitz, K. M. Giacomini, and A. G. Clark. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13:481-494 (2003).
23. S. Saito, A. Iida, A. Sekine, Y. Miura, C. Ogawa, S. Kawauchi, S. Higuchi, and Y. Nakamura. Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population. J. Hum. Genet. 47:38-50 (2002).
24. M. Tanabe, I. Ieiri, N. Nagata, K. Inoue, S. Ito, Y. Kanamori, M. Takahashi, Y. Kurata, J. Kigawa, S. Higuchi, N. Terakawa, and K. Otsubo. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 297:1137-1143 (2001).
25. S. Hoffmeyer, O. Burk, O. von Richter, H. P. Arnold, J. Brockmoller, A. Johne, I. Cascorbi, T. Gerloff, I. Roots, M. Eichelbaum, and U. Brinkmann. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P- glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97:3473-3478 (2000).
26. S. Ito, I. Ieiri, M. Tanabe, A. Suzuki, S. Higuchi, and K. Otsubo. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11:175-184 (2001).
27. I. Cascorbi, T. Gerloff, A. Johne, C. Meisel, S. Hoffmeyer, M. Schwab, E. Schaeffeler, M. Eichelbaum, U. Brinkmann, and I. Roots. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 69:169-174 (2001).
28. K. Tang, S. M. Ngoi, P. C. Gwee, J. M. Chua, E. J. Lee, S. S. Chong, and C. G. Lee. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12:437-450 (2002).
29. A. G. Clark, K. M. Weiss, D. A. Nickerson, S. L. Taylor, A. Buchanan, J. Stengard, V. Salomaa, E. Vartiainen, M. Perola, E. Boerwinkle, and C. F. Sing. Haplotype structure and population genetic inferences from nucleotide-sequence variation in human lipoprotein lipase. Am. J. Hum. Genet. 63:595-612 (1998).
30. M. Stephens, N. J. Smith, and P. Donnelly. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68:978-989 (2001).
31. G. Chen, G. E. Duran, K. A. Steger, N. J. Lacayo, J. P. Jaffrezou, C. Dumontet, and B. I. Sikic. Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. J. Biol. Chem. 272:5974-5982 (1997).
32. S. V. Ambudkar, S. Dey, C. A. Hrycyna, M. Ramachandra, I. Pastan, and M. M. Gottesman. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39:361-398 (1999).
33. T. Hoof, A. Demmer, M. R. Hadam, J. R. Riordan, and B. Tummler. Cystic fibrosis-type mutational analysis in the ATP-binding cassette transporter signature of human P-glycoprotein MDR1. J. Biol. Chem. 269:20575-20583 (1994).
34. C. Kimchi-Sarfaty, J. J. Gribar, and M. M. Gottesman. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 62:1-6 (2002).
35. N. Morita, T. Yasumori, and K. Nakayama. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem. Pharmacol. 65:1843-1852 (2003).
36. M. Hitzl, S. Drescher, H. van der Kuip, E. Schaffeler, J. Fischer, M. Schwab, M. Eichelbaum, and M. F. Fromm. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11:293-298 (2001).
37. K. Oselin, T. Gerloff, P. M. Mrozikiewicz, R. Pahkla, and I. Roots. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam. Clin. Pharmacol. 17:463-469 (2003).
38. A. Johne, K. Kopke, T. Gerloff, I. Mai, S. Rietbrock, C. Meisel, S. Hoffmeyer, R. Kerb, M. F. Fromm, U. Brinkmann, M. Eichelbaum, J. Brockmoller, I. Cascorbi, and I. Roots. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 72:584-594 (2002).
39. Y. Kurata, I. Ieiri, M. Kimura, T. Morita, S. Irie, A. Urae, S. Ohdo, H. Ohtani, Y. Sawada, S. Higuchi, and K. Otsubo. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin. Pharmacol. Ther. 72:209-219 (2002).
40. T. Sakaeda, T. Nakamura, M. Horinouchi, M. Kakumoto, N. Ohmoto, T. Sakai, Y. Morita, T. Tamura, N. Aoyama, M. Hirai, M. Kasuga, and K. Okumura. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 18:1400-1404 (2001).
41. M. Horinouchi, T. Sakaeda, T. Nakamura, Y. Morita, T. Tamura, N. Aoyama, M. Kasuga, and K. Okumura. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm. Res. 19:1581-1585 (2002).
42. T. Gerloff, M. Schaefer, A. Johne, K. Oselin, C. Meisel, I. Cascorbi, and I. Roots. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br. J. Clin. Pharmacol. 54:610-616 (2002).
43. S. Drescher, E. Schaeffeler, M. Hitzl, U. Hofmann, M. Schwab, U. Brinkmann, M. Eichelbaum, and M. F. Fromm. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. 53:526-534 (2002).
44. D. Anglicheau, C. Verstuyft, P. Laurent Puig, L. Becquemont, M. H. Schlageter, B. Cassinat, P. Beaune, C. Legendre, and E. Thervet. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol. 14:1889-1896 (2003).
45. C. R. Yates, W. Zhang, P. Song, S. Li, A. O. Gaber, M. Kotb, M. R. Honaker, R. R. Alloway, and B. Meibohm. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J. Clin. Pharmacol. 43:555-564 (2003).
46. I. A. Macphee, S. Fredericks, T. Tai, P. Syrris, N. D. Carter, A. Johnston, L. Goldberg, and D. W. Holt. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74:1486-1489 (2002).
47. H. Zheng, S. Webber, A. Zeevi, E. Schuetz, J. Zhang, P. Bowman, G. Boyle, Y. Law, S. Miller, J. Lamba, and G. J. Burckart. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am. J. Transplant. 3:477-483 (2003).
48. N. von Ahsen, M. Richter, C. Grupp, B. Ringe, M. Oellerich, and V. W. Armstrong. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem. 47:1048-1052 (2001).
49. D. A. Hesselink, H. Ngyuen, M. Wabbijn, P. J. Gregoor, E. W. Steyerberg, I. C. Van Riemsdijk, W. Weimar, and T. Van Gelder. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br. J. Clin. Pharmacol. 56:327-330 (2003).
50. J. Fellay, C. Marzolini, E. R. Meaden, D. J. Back, T. Buclin, J. P. Chave, L. A. Decosterd, H. Furrer, M. Opravil, G. Pantaleo, D. Retelska, L. Ruiz, A. H. Schinkel, P. Vernazza, C. B. Eap, and A. Telenti. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30-36 (2002).
51. W. Siegmund, K. Ludwig, T. Giessmann, P. Dazert, E. Schroeder, B. Sperker, R. Warzok, H. K. Kroemer, and I. Cascorbi. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther. 72:572-583 (2002).
52. J. F. Watchko, M. J. Daood, and T. W. Hansen. Brain bilirubin content is increased in P-glycoprotein-deficient transgenic null mutant mice. Pediatr. Res. 44:763-766 (1998).
53. L. F. Marques-Santos, R. R. Bernardo, E. F. de Paula, and V. M. Rumjanek. Cyclosporin A and trifluoperazine, two resistance-modulating agents, increase ivermectin neurotoxicity in mice. Pharmacol. Toxicol. 84:125-129 (1999).
54. R. L. Roberts, P. R. Joyce, R. T. Mulder, E. J. Begg, and M. A. Kennedy. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2:191-196 (2002).
55. A. Yamauchi, I. Ieiri, Y. Kataoka, M. Tanabe, T. Nishizaki, R. Oishi, S. Higuchi, K. Otsubo, and K. Sugimachi. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74:571-572 (2002).
56. A. J. Sadeque, C. Wandel, H. He, S. Shah, and A. J. Wood. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther. 68:231-237 (2000).
57. C. Pauli-Magnus, J. Feiner, C. Brett, E. Lin, and D. L. Kroetz. No effect of MDR1 C3435T polymorphisms on disposition and brain entry of loperamide. Clin Pharm Ther 74:487-498 (2003).
58. T. Furuno, M. T. Landi, M. Ceroni, N. Caporaso, I. Bernucci, G. Nappi, E. Martignoni, E. Schaeffeler, M. Eichelbaum, M. Schwab, and U. M. Zanger. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 12:529-534 (2002).
59. M. Drozdzik, M. Bialecka, K. Mysliwiec, K. Honczarenko, J. Stankiewicz, and Z. Sych. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 13:259-263 (2003).
60. A. Siddiqui, R. Kerb, M. E. Weale, U. Brinkmann, A. Smith, D. B. Goldstein, N. W. Wood, and S. M. Sisodiya. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348:1442-1448 (2003).
61. M. Schwab, E. Schaeffeler, C. Marx, M. F. Fromm, B. Kaskas, J. Metzler, E. Stange, H. Herfarth, J. Schoelmerich, M. Gregor, S. Walker, I. Cascorbi, I. Roots, U. Brinkmann, U. M. Zanger, and M. Eichelbaum. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 124:26-33 (2003).
62. M. Siegsmund, U. Brinkmann, E. Schaffeler, G. Weirich, M. Schwab, M. Eichelbaum, P. Fritz, O. Burk, J. Decker, P. Alken, U. Rothenpieler, R. Kerb, S. Hoffmeyer, and H. Brauch. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J. Am. Soc. Nephrol. 13:1847-1854 (2002).
63. M. M. van den Heuvel-Eibrink, E. A. Wiemer, M. J. de Boevere, B. van der Holt, P. J. Vossebeld, R. Pieters, and P. Sonneveld. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood 97:3605-3611 (2001).
64. T. Illmer, U. S. Schuler, C. Thiede, U. I. Schwarz, R. B. Kim, S. Gotthard, D. Freund, U. Schakel, G. Ehninger, and M. Schaich. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 62:4955-4962 (2002).
65. A. Kafka, G. Sauer, C. Jaeger, R. Grundmann, R. Kreienberg, R. Zeillinger, and H. Deissler. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int. J. Oncol. 22:1117-1121 (2003).
66. I. Ifergan, N. F. Bernard, J. Bruneau, M. Alary, C. M. Tsoukas, and M. Roger. Allele frequency of three functionally active polymorphisms of the MDR-1 gene in high-risk HIV-negative and HIV-positive Caucasians. AIDS 16:2340-2342 (2002).
67. Z. L. Brumme, W. W. Dong, K. J. Chan, R. S. Hogg, J. S. Montaner, M. V. O'Shaughnessy, and P. R. Harrigan. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 17:201-208 (2003).
68. M. Nasi, V. Borghi, M. Pinti, C. Bellodi, E. Lugli, S. Maffei, L. Troiano, L. Richeldi, C. Mussini, R. Esposito, and A. Cossarizza. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 17:1696-1698 (2003).